Suppr超能文献

社会经济地位对接受处方受限噻唑烷二酮类药物(TZDs)可能性的影响。

Impact of the socioeconomic status on the probability of receiving formulary restricted thiazolidine (TZDs).

作者信息

Dorais Marc, LeLorier Jacques

机构信息

Research group in Pharmacoepidemiology and Pharmacoeconomics, Research Center, Centre Hospitalier de l'Université de Montréal - Hôtel-Dieu (CHUM), Montréal, Québec.

出版信息

Can J Clin Pharmacol. 2008 Winter;15(1):e15-21. Epub 2008 Jan 9.

Abstract

BACKGROUND

In the province of Quebec, Canada, the reimbursement of thiazolidinediones (TZDs) is limited to patients who do not respond to doses of metformin and a sulfonylurea.

OBJECTIVES

The objective of this research project was to study, in a real-life setting, the ârisk factorsâ for receiving these restricted drugs among patients who meet the reimbursement criteria.

METHODS

Among patients eligible for drug coverage under the RAMQ between May 2000 and June 2005, we selected those who received six consecutive dispensations of high doses of both metformin and a sulfonylurea. The date of the sixth dispensation was set as the index date. The proportion of patients who received a TZD in the year following the index date was calculated and a logistic regression was used to estimate the impact of several factors on the probability of receiving a TZD.

RESULTS

There were 4,836 patients in the cohort. A TZD was dispensed to 24.9% (95% CI: 23.7%;26.2%) of the patients. Compared to the oldest group of patients (65 years and more), the probability to receive a TZD was higher for patients aged 51 to 64 years (OR=1.33 95% CI: 1.11;1.59) and patients aged 19 to 50 years [OR=1.81 (95% CI: 1.40;2.33)]. Patients with the highest income were more likely to receive a TZD (OR=1.55 95% CI: 1.21;1.98) compared to patients with the lowest income.

CONCLUSIONS

These findings suggest that the restricted access to TZDs probably results in social inequities, as individuals with lower incomes are less likely to receive these drugs. Key words: Restricted drugs, TZDs, diabetes.

摘要

背景

在加拿大魁北克省,噻唑烷二酮类药物(TZDs)的报销仅限于对二甲双胍和磺脲类药物剂量无反应的患者。

目的

本研究项目的目的是在现实环境中研究符合报销标准的患者中接受这些受限药物的“风险因素”。

方法

在2000年5月至2005年6月期间有资格获得魁北克医疗保险局(RAMQ)药物保险的患者中,我们选择了那些连续六次获得高剂量二甲双胍和磺脲类药物配药的患者。第六次配药日期被设定为索引日期。计算索引日期后一年内接受TZDs的患者比例,并使用逻辑回归估计几个因素对接受TZDs概率的影响。

结果

该队列中有4836名患者。24.9%(95%可信区间:23.7%;26.2%)的患者接受了TZDs配药。与最年长的患者组(65岁及以上)相比,51至64岁的患者接受TZDs的概率更高(比值比=1.33,95%可信区间:1.11;1.59),19至50岁的患者[比值比=1.81(95%可信区间:1.40;2.33)]。与收入最低的患者相比,收入最高的患者更有可能接受TZDs(比值比=1.55,95%可信区间:1.21;1.98)。

结论

这些发现表明,TZDs的受限获取可能导致社会不平等,因为低收入个体获得这些药物 的可能性较小。关键词:受限药物、TZDs、糖尿病。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验